GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Cash Receipts from Securities Related Activities

Biogen (BUE:BIIB) Cash Receipts from Securities Related Activities


View and export this data going back to 2019. Start your Free Trial

What is Biogen Cash Receipts from Securities Related Activities?

Cash Receipts from Securities Related Activities only applicable to companies reporting Cash Flow from Operations in direct method.


Biogen Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Cash Receipts from Securities Related Activities
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.